drugset / Trial / NCT01215266
Sorafenib in Urothelium Cancer of Bladder
Phase 2
Terminated
98 enrolled
Association of Urologic Oncology (AUO)
University Hospital, Essen · collab
RandomizedSingle-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the use of Sorafenib additionally to gemcitabine and cisplatin in bladder cancer.
Timeline
- Start
- 2006-10
- Primary completion
- 2011-06
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sorafenib | Small molecule | 800 mg | — |